Daniel Lawrence
CSL Limited
7 Papers
15 Citations
Daniel Lawrence is an academic researcher from CSL Limited. The author has contributed to research in topics: Stroke & Plasminogen activator. The author has an hindex of 2, co-authored 7 publications. Previous affiliations of Daniel Lawrence include Ludwig Institute for Cancer Research.
Chat about Author
Papers
Patent
Methods and compositions for modulation of blood-neural barrier
Ulf Eriksson,Daniel Lawrence,Enming Joe Su,Dudley K. Strickland,Manuel Yepes,Linda Fredriksson +5 more
- 17 Apr 2007
TL;DR: In this paper, an improved tPA treatment of ischemic cerebrovascular and related diseases in combination with antagonism of the PDGF signaling pathway was proposed for conjunctive therapy of stroke using tPA and an anti PDGF-C antagonist or an anti-PDGFR-α antagonist.
8
Patent
Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
Daniel Lawrence,Manuel S. Yepes,Dudley K. Strickland +2 more
- 20 May 2004
TL;DR: In this paper, the authors proposed a method of reducing vascular permeability in tissue of a subject comprising inhibiting the activity of serine proteinase tissue-type plasminogen activator (tPA).
6
Patent
Method of treating or preventing stroke
Ulf Eriksson,Ingrid Nilsson,Daniel Lawrence,Enming Joe Su +3 more
- 25 May 2017
TL;DR: In this paper, a method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling was proposed.
1
Patent
Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
Ulf Eriksson,Ingrid Nilsson,Daniel Lawrence,Enming Joe Su +3 more
- 30 Mar 2021
TL;DR: In this paper, a method of reducing an effect of stroke in a subject, the method comprising administering to the subject a compound that inhibits VEGF-B signaling was proposed.